Abacavir Composition for TDP1-Deficient Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for adult T-cell leukemia and lung cancer lacking TDP1 expression face challenges in effectively targeting cancer cells without harming normal cells, as existing nucleoside analogue reverse transcriptase inhibitors like zidovudine have unknown mechanisms and side effects on normal DNA replication.
Innovation Solution
A pharmaceutical composition comprising abacavir or its pharmaceutically acceptable derivatives, which induces DNA double-strand breaks in cancer cells and exhibits anti-cancer activity specifically in TDP1-deficient cells, potentially combined with PARP or topoisomerase inhibitors to enhance efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogue reverse transcriptase inhibitors like zidovudine are used to treat cancer cells, then anti-cancer activity is achieved, but DNA replication of normal cells is inhibited causing side effects
Solution Approach 1:
The patent applies local quality by targeting cancer cells with specific molecular characteristics (TDP1 expression levels, DNA repair deficiencies) rather than treating all cells uniformly. Abacavir and combination therapies are designed to exploit the specific vulnerabilities of cancer cells while sparing normal cells through selective mechanisms of action.
Solution Approach 2:
The patent employs composite materials by combining abacavir with PARP inhibitors and/or topoisomerase inhibitors to create a multi-component therapeutic regimen. This combination approach synergistically enhances anti-cancer activity while allowing each component to contribute differently to the overall therapeutic effect, thereby improving the therapeutic index.
2Reliability
If abacavir is used to induce DNA double-strand breaks in cancer cells, then cancer cell proliferation is suppressed, but the mechanism of action must be highly specific to avoid normal cell damage
Solution Approach 1:
The patent uses intermediaries by employing PARP inhibitors and topoisomerase inhibitors as mediators that work in conjunction with abacavir. These intermediary agents enhance the DNA-damaging effects on cancer cells while providing additional layers of selectivity through their own mechanisms of action, which complement abacavir's activity.
Solution Approach 2:
The patent applies parameter changes by exploiting differences in DNA repair capacity, TDP1 expression levels, and cellular sensitivity to DNA damage between cancer and normal cells. These parameter differences are leveraged to achieve selective toxicity toward cancer cells while preserving normal cell function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Abacavir demonstrates selective suppression of cancer cell proliferation and induction of DNA breaks in TDP1-deficient cells, reducing side effects on normal cells and showing synergistic effects with other inhibitors, thereby providing a targeted therapeutic approach for adult T-cell leukemia and lung cancer.
Implementation Method 1
abacavir or a pharmaceutically acceptable salt, solvate, ester or salt of the ester thereof induces DNA double-strand break in cancer cells of adult T-cell leukemia or lung cancer lacking TDP1 expression
Data Source
Figure 1(A)~1(B)
Figure 2(A)~2(B)
Figure 3(A)~3(D)
AI summary
Abacavir, a nucleoside analogue reverse transcriptase inhibitor, has been found to exhibit an anti-cancer activity on ATL cells in vitro without inhibiting DNA replication of normal cells. Abacavir or a pharmaceutically acceptable derivative thereof is useful as an active ingredient of a pharmaceutical composition for use in the prevention or the treatment of cancer, in particular a cancer whose DNA repair system is impaired such as breast cancer or adult T-cell leukemia.